The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

被引:0
|
作者
Carlo Pincelli
Eric Henninger
Florence Casset-Semanaz
机构
[1] University of Modena and Reggio Emilia,Department of Medicine, Institute of Dermatology
[2] Serono International S.A. ,undefined
来源
Archives of Dermatological Research | 2007年 / 298卷
关键词
Arthropathy; Arthritis; Efalizumab; Psoriasis; Psoriatic arthritis;
D O I
暂无
中图分类号
学科分类号
摘要
A large-scale, pooled analysis of safety data from five Phase III clinical trials (including open-label extensions of two of these studies) and two Phase III open-label clinical trials of efalizumab was conducted to explore whether arthropathy adverse events (AEs) were associated with efalizumab treatment in patients with moderate-to-severe chronic plaque psoriasis. Data from patients who received subcutaneous injections of efalizumab or placebo were stratified for analysis into phases according to the nature and duration of treatment. These included: the ‘first treatment’ phase (0–12-week data from patients who received either efalizumab, 1 mg/kg once weekly, or placebo in the five placebo-controlled studies); the ‘extended treatment’ phase (13–24-week data from seven trials for all efalizumab-treated patients); and the ‘long-term treatment’ phase (data from efalizumab-treated patients who received treatment for up to 36 months in two long-term trials). Descriptive statistics were performed and the incidence of arthropathy AEs per patient-year was calculated using 95% confidence intervals (CIs). During the first treatment phase, a similar proportion of patients had an arthropathy AE in the efalizumab group (3.3%; 58/1740 patients) compared with the placebo group (3.5%; 34/979 patients); the incidence of arthropathy AEs per patient-year was 0.15 in the efalizumab group (95% CI 0.11–0.19) and 0.16 in the placebo group (95% CI 0.11–0.22). Analysis of first treatment phase data from one study (n = 793) showed that the incidence of psoriatic arthropathy per patient-year was lower in efalizumab-treated patients (0.10; 95% CI 0.05–0.18) than in those given placebo (0.17; 95% CI 0.08–0.30). During the extended treatment phase, the incidence of arthropathy remained low (0.17; 95% CI 0.14–0.22). Data from two long-term studies showed that there was no increase in the incidence of arthropathy AEs over time in patients treated with efalizumab for up to 36 months. Patients who had an arthropathy AE during treatment with efalizumab appeared to be more likely to have a history of arthropathy prior to treatment. Efalizumab does not appear to increase the risk of arthropathy AEs compared with placebo.
引用
收藏
页码:329 / 338
页数:9
相关论文
共 50 条
  • [21] LONG-TERM SAFETY OF TEDUGLUTIDE TREATMENT FOR PATIENTS WITH INTESTINAL FAILURE ASSOCIATED WITH SHORT BOWEL SYNDROME: POOLED DATA FROM 4 CLINICAL TRIALS
    Gabe, S. M.
    Pape, U-F
    Delmaestro, E.
    Li, B.
    Youssef, N. N.
    Seidner, D.
    GUT, 2016, 65 : A109 - A110
  • [22] Incidence of Treatment-Emergent Adverse Events (TEAEs) According to Baseline Antiepileptic Drug (AED) Use: A Pooled Analysis of Data from Phase II/III Trials of Adjunctive Eslicarbazepine Acetate (ESL) in Children
    Wirrell, Elaine
    Loddenkemper, Tobias
    Conry, Joan
    Grinnell, Todd
    Cantu, David
    Gama, Helena
    Rocha, Francisco
    Li, Yan
    Blum, David
    NEUROLOGY, 2018, 90
  • [23] Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials
    Hughes, Derralynn A.
    Gonzalez, Derlis E.
    Lukina, Elena A.
    Mehta, Atul
    Kabra, Madhulika
    Elstein, Deborah
    Kisinovsky, Isaac
    Giraldo, Pilar
    Bavdekar, Ashish
    Hangartner, Thomas N.
    Wang, Nan
    Crombez, Eric
    Zimran, Ari
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (07) : 584 - 591
  • [24] Long-term Follow-up of Patients with Unstable Angina Treated with Drug-Eluting Stents: Pooled Analysis from 14 Clinical Trials
    Nikolsky, Evgenia
    Mehran, Roxana
    Dangas, George
    Ellis, Stephen G.
    Lansky, Alexandra J.
    Fahy, Martin
    Donohoe, Dennis
    Stone, Gregg W.
    Leon, Martin B.
    Moses, Jeffrey W.
    CIRCULATION, 2008, 118 (18) : S970 - S970
  • [25] Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions
    Ferreira, J. J.
    Lees, A.
    Rocha, J. -F.
    Poewe, W.
    Rascol, O.
    Soares-da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (07) : 953 - 960
  • [26] Niacin Extended-Release Therapy in Phase III Clinical Trials is Associated with Relatively Low Rates of Drug Discontinuation due to Flushing and Treatment-Related Adverse Events A Pooled Analysis
    Brinton, Eliot A.
    Kashyap, Moti L.
    Vo, Anthony N.
    Thakkar, Roopal B.
    Jiang, Ping
    Padley, Robert J.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2011, 11 (03) : 179 - 187
  • [27] Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis.
    Genovese, Mark C.
    Kremer, Joel M.
    van Vollenhoven, Ronald F.
    Alten, Rieke
    Jose Scali, Juan
    Kelman, Ariella
    Rowell, Lucy
    Pitts, Laura
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S201 - S201
  • [28] Long-Term Quality of Life in Patients With Focal Seizures Treated With ESL: Pooled Analysis From 3 Phase III Open-Label Extension Studies
    Cantu, David
    Krishnaiengar, Suparna
    Thomases, Daniel
    Mehta, Darshan
    Hall, Diane
    Zhang, Yi
    Gama, Helena
    Pereira, Ana
    Grinnell, Todd
    NEUROLOGY, 2023, 100 (17)
  • [29] Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials
    Citrome, Leslie
    Meng, Xiangyi
    Hochfeld, Marla
    Stahl, Stephen M.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2012, 27 (01) : 24 - 32
  • [30] Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression br
    Williamson, David J.
    Gogate, Jagadish R.
    Sliwa, Jennifer K. Kern
    Manera, Lewis S.
    Preskorn, Sheldon H.
    Winokur, Andrew
    Starr, Lynn
    Starr, H. Lynn
    Daly, Ella J.
    JOURNAL OF CLINICAL PSYCHIATRY, 2022, 83 (06)